[The efficacy and safety in the treatment of chronic abacterial prostatitis/chronic pelvic pain syndrome after intraprostatic injection of Chuanshentong].

Article

Author: Zhao, Xiao-kun ; Yang, Ju-yun ; Liu, Ren ; Liu, Zi-ting ; Liao, Hai-qiu ; Yang, Jin-rui ; Yang, Luo-yan

OBJECTIVETo assess the clinic efficacy and safety in the treatment of chronic abacterial prostatitis/chronic pelvic pain syndrome (CABP/CPPS) after intraprostatic injection of Chuanshentong.METHODSFive milliliter of solution blending Chuanshentong and lidocaine was transperineally injected into one lobe of prostate, once a day for 6 days, for a total of 98 cases of patients who had been diagnosed as chronic abacterial prostatitis/chronic pelvic pain syndrome. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index (CPSI) after a 12 week follow-up.RESULTSAll cases had completed the follow-up. Fifty-three cases (54.08%) were completely cured, accompanied by remarkable effective in 17 cases (17.35%) and improved in 23 cases (23.47%). The total remarkable efficacy was 71.43% and improved 94. 90%. Scores of CPSI decreased significantly compared with pre-treatment (95% confidence interval 12.85 approximately 17.91).CONCLUSIONIt is suggested that transperineally intraprostatic injection of Chuanshentong may be a useful method for the treatment of CABP/CPPS.

01 Mar 2004·Zhonghua nan ke xue = National journal of andrology

[Efficacy and safety of intraprostatic injection of chuanshentong for chronic abacterial prostatitis/chronic pelvic pain syndrome].

Article

Author: He, Huixu ; Hu, Weilie ; Wang, Wei ; Wang, Yuanli ; Zhang, Xiaoming

OBJECTIVETo evaluate the efficacy and safety of intraprostatic injection of Chuanshentong in the treatment of chronic abacterial prostatitis/chronic pelvic pain syndrome(CAP/CPPS).METHODSRandomized, double blinded, placebo controlled trials were carried out from September 2002 to March 2003. A total of 38 patients with diagnosed CAP/CPPS, 24 experimental and 14 controls, were analyzed. In the trial group, 6 ml of mixed solution of Chuanshentong and lidocaine was transperineally injected into one lobe of the prostate, once a day for 6 days. Likewise, the control group was treated with placebo containing lidocaine. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index(CPSI) after a 6-week follow-up. The main semen parameters before and after 3-month treatment were compared.RESULTSIn the trial group, 13 cases (56.5%) were completely cured, 5 cases(21.7%) showed remarkable effect, and 4 cases (17.4%) were improved. While in the control group, effectiveness was shown in only 2 cases (15.4%), and improvement in 3 cases (23%). CPSI scores decreased significantly after treatment(95% of confidence interval: 17.97-23.08). Chuanshentong solution had no obvious impact on the main semen parameters. No severe adverse effects were observed.CONCLUSIONTransperineal intraprostatic injection of Chuanshentong is a safe and effective method for the treatment of CAP/CPPS.

01 Jan 1994·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical and experimental study of benign prostatic hyperplasia with intraglandular injection of chuan shen tong].

Article

Author: Lu, F N ; Zhao, Y J

1038 cases of benign prostatic hyperplasia (BPH) were treated by injection of Chuan Shen Tong (CST), a Chinese herbal medicine, into the prostate gland. At the end of treatment the effective rate was 96%. After the treatment the BPH with urodynamic measurement was studied and it was found that the peak flow rate and mean flow rate increased 18% and 41.8% respectively. Transabdominal and transrectal ultrasonographies were used to measure the shrinkage of prostate's size after the injection treatment to be 0.51 and 0.4 cm (mean diameter) respectively. Animal model of BPH was established by the testosterone propionate. The prostatic weight and prostatic index was measured in mice after the injection of CST, it significantly decreased compared with that of the control (P < 0.01). The pathological findings: The hyperplastic papillae disappeared and the body of prostate markedly shrank in size. Experiment dogs has been carried out for the prostate quantitative analysis. The result revealed that the prostate parenchyma and intercellular substance shrank to 26.8% and 4.5% respectively.

100 Deals associated with ChuanShenTong

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostatic Hyperplasia	CN	Guizhou Ruihe Pharmaceutical Co., Ltd.	01 Jan 1998

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ChuanShenTong

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation